** Hong Kong-listed shares of RemeGen Co Ltd 9995.HK jump 7% to HK$52.90, their highest levels since April 2023
** Shanghai-listed stock of the Chinese biopharmaceuticals developer 688331.SS rise 4.7% to 59.33 yuan, its highest point since April 2024
** Nomura maintains "neutral" rating but lifts TP of RemeGen Hong Kong shares to HK$47.6 from HK$16.37 and the Shanghai stock to 57.76 yuan from 29.80 yuan, citing the firm's new H-shares issuance improves its financials
** "We believe the current strong sentiment on biotech names provides a good timing window for the company to make this issuance," Nomura said, adding the proceeds will strengthen the company's constrained cash position
** RemeGen says to issue 19 mln H-shares at HK$42.44 apiece, raising HK$806.4 mln ($103 mln)
** Hang Seng Biotech Index .HSHKBIO rises 2.2% and Hang Seng Index .HSI gains 0.7%
** YTD, Hong Kong stock up 258.3%, Shanghai shares up 90.5%
($1 = 7.8298 Hong Kong dollars)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.